🇺🇸 FDA
Patent

US 9265827

Anti-PDGFR-beta antibodies and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9265827 (Anti-PDGFR-beta antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/179, A61K39/39541